OBJECTIVE:To find the active ingredient of on antithrombotic chuanxiong rhizoma using computer aided drug de-sign. METHODS:Usingthrombosisas keyword,thrombosis related proteins were searched and screened in therapeutic target da-tabase;target proteins'three-dimensional structure were downloaded in protein database,then the protein preparing tool were used to determine the coordinates of the active area center. PyRx software and Discovery Studio Visualizer were used to match the 247 small molecules of chuanxiong rhizoma with target protein that downloaded from Taiwan traditional Chinese medicine database. The active molecules were screened and binding force was analyzed. RESULTS:Active molecules of neochlorogenic acid,1-H-benz-imidazole-2-amine,3,8-dihydrodiligustilide,chuanxiongterpene were selected by blinding energy,and there were high binding ac-tivity among these active molecules,thrombin,antithrombinⅢ,coagulation factorⅩa and thrombomodulin,and the binding ener-gy were -6.1,-4.5,-7.7,-8.6 kJ/mol. Analysis results showed van Edward force and electrostatic interactions played an im-portant role in their respective docking. CONCLUSIONS:Neochlorogenic acid,1-H-benzimidazole-2-amine,3,8-dihydrodiligusti-lide,chuanxiongterpene may be the antithrombotic activity ingredients of Chuanxiong rhizoma.

Objective To evaluate the antineoplastic effect of laser immunotherapy in mice with multiple cutaneous squamous cell carcinoma (CSCC).Methods Normal immunocompetent hairless SKH-1 mice were consecutively irradiated by ultraviolet rays to establish mouse models of multiple CSCC.Then,20 CSCC-bearing mice were randomly and equally divided into 4 groups:laser group irradiated with an 808-nm near-infrared laser (1 W/cm2,10 minutes) once every two weeks for a total of 3 sessions,laser immunotherapy group irradiated with an 808-nm nearinfrared laser as above and topically treated with imiquimod cream once a day for 3 days before and after each session of irradiation,imiquimod group treated with imiquimod cream as in the laser immunotherapy group,and control group receiving no treatment.The volume of tumors was calculated,and their morphology as well as the survival of mice were observed after the treatment.The t test and Mantel-Cox log-rank test were used to compare the volume of tumors on the dorsum and survival rates of mice,respectively,on days 27 and 60 after the start of treatment.Another 12 CSCC-bearing mice were randomly and equally divided into the 4 groups mentioned above,and tumor tissues were resected from these mice for histopathological examination on day 5 after the first treatment.Results On day 27,the volume of tumors significantly increased in the control group and imiquimod group (both P ＜ 0.05),but experienced no significant increase in either of the other two groups compared with that before the start of treatment (both P ＞ 0.05).Moreover,the volume of tumors in the control group was slightly larger than that in the imiquimod group (P ＞ 0.05),but significantly larger than that in the laser group and laser immunotherapy group (both P ＜ 0.05).The volume of tumors in the laser group increased,and was significantly larger than that in the laser immunotherapy group on day 60 (P ＜ 0.05).Mice all died within 40 days in the control group,and within 50 days in the imiquimod group;one mouse died on days 52 and 53 separately,and the other mice all survived longer than 60 days in the laser group;no mice died within 60 days in the laser immunotherapy group.By day 60,the survival time of mice was slightly longer in the imiquimod group (P ＞ 0.05),significantly longer in the laser group and laser immunotherapy group compared with the control group (both P ＜ 0.05),but similar between the laser group and laser immunotherapy group (P ＞ 0.05).Histopathological examination showed that 5-day topical application of imiquimod cream did not cause death of tumor cells,but numerous tumor cells died in the laser group and laser immunotherapy group.Multiple inflammatory cells were observed around the tumors,and the number of the inflammatory cells was obviously larger in both the laser group and laser immunotherapy group,especially in the latter group,compared with the control group.Conclusion Laser immunotherapy is a new effective and safe treatment for CSCC in mice,and has potential value especially in the treatment of multiple or metastatic CSCC.

Objective To explore and assess the reasonable application of integrated collaborative service mode in obstetrics and gynecology clinical service.Methods 152 pregnant women admitted in obstetric outpatient from March 2016 to May 2016 were randomly assigned into observation group and control group,76 cases in each group.The control group received obstetric traditional outpatient treatment and hospitalization mode,while the observation group implemented the integrated collaborative service mode.It was a integrated mode based on the traditional mode and multidisciplinary professionals integrated into groups for synergistic services,from the beginning of pregnancy to discharge.Results The number of cases who were knowledged maternal diseases,intraoperative coordination,reasonable diet and breastfeeding of the observation group (69,70,69,66) were superior to those of the control group (51,40,54,50) (x2=17.56,52.58,12.44,11.11,all P<0.001).The incidence rate of maternal and neonatal complications of the observation group were significantly lower than those of the control group(t=12.04,6.49,2.87,9.26,-7.14,all P<0.005).And patients satisfaction survey was improved,the number of satisfaction and complaint in the observation group was 70 persons,1 person,which of the control group was 70 persons,6 persons (x2=7.65,P<0.01).Conclusion Integrated collaborative service mode can improve the quality of medical service and patients' satisfaction,while reduce cesarean section rate,postpartum hemorrhage and maternal complications.Integrated collaborative service mode is an effective method to promote the development of perinatal medicine.

Objective To observe the vaccination reactions and immunogenicity of the application of lyophilized Vero cell rabies vaccine without adjuvant in a way of low-dose intradermal injection for post-exposure group. Methods Conducting post-exposure immunization for 256 persons with the class Ⅱ level exposure to rabies. Based on a randomized, single-blind principle, all subjects were divided into intradermal injection (ID) group (n= 128),injected 0.1 ml for each site in accordance with 0,3,7,28,90 d,2 sites,2 sites,2sites,1 site,1 site respectively, and intramuscular injection(IM) group(n= 128) in accordance with 0,3,7,14,28 d in full-volume (0.5ml) PVRV Deltoid injection. The local and systemic vaccination reactions were observed for the different injection ways. The indirect sandwich ELISA assay was used to analyze the antibody levels. Results For the intradermal injection group, the incidence rates for local redness and swelling, induration, pain, itch were 1.27%, 0.29% ,0.49% ,11.43% respectively,for the intramuscular group, the incidence rates were 1.09% ,0. 16% ,2. 81% ,1.41% respectively. From the point of systemic reactions,the incidence rates of fever,rash,headache,fatigue and weakness were 0.31 % ,0. 16% ,0. 31 % , 1.09% respectively in the intradermal injection group,and the rates were 0.31% ,0.31% ,0.63% , 1.09% respectively in intramuscular group. All the adverse effects often occurred following the 1st,2nd injection. The seroconversion rates for intradermal injection and intramuscular were 94.53% ,95.31% following 14 d immunization respectively,the rates were 96. 83% ,97.64% following 42 d immunization respectively. For the post-exposure group,no statistical difference in significance was found between the two seroconversion rates. Conclusion For the application of domestic lyophilized Vero cell rabies vaccine,its adverse reactions are mild,and immunogenicity is good.